Miller, A.L.; Garcia, P.L.; Fehling, S.C.; Gamblin, T.L.; Vance, R.B.; Council, L.N.; Chen, D.; Yang, E.S.; van Waardenburg, R.C.A.M.; Yoon, K.J.
The BET Inhibitor JQ1 Augments the Antitumor Efficacy of Gemcitabine in Preclinical Models of Pancreatic Cancer. Cancers 2021, 13, 3470.
https://doi.org/10.3390/cancers13143470
AMA Style
Miller AL, Garcia PL, Fehling SC, Gamblin TL, Vance RB, Council LN, Chen D, Yang ES, van Waardenburg RCAM, Yoon KJ.
The BET Inhibitor JQ1 Augments the Antitumor Efficacy of Gemcitabine in Preclinical Models of Pancreatic Cancer. Cancers. 2021; 13(14):3470.
https://doi.org/10.3390/cancers13143470
Chicago/Turabian Style
Miller, Aubrey L., Patrick L. Garcia, Samuel C. Fehling, Tracy L. Gamblin, Rebecca B. Vance, Leona N. Council, Dongquan Chen, Eddy S. Yang, Robert C. A. M. van Waardenburg, and Karina J. Yoon.
2021. "The BET Inhibitor JQ1 Augments the Antitumor Efficacy of Gemcitabine in Preclinical Models of Pancreatic Cancer" Cancers 13, no. 14: 3470.
https://doi.org/10.3390/cancers13143470
APA Style
Miller, A. L., Garcia, P. L., Fehling, S. C., Gamblin, T. L., Vance, R. B., Council, L. N., Chen, D., Yang, E. S., van Waardenburg, R. C. A. M., & Yoon, K. J.
(2021). The BET Inhibitor JQ1 Augments the Antitumor Efficacy of Gemcitabine in Preclinical Models of Pancreatic Cancer. Cancers, 13(14), 3470.
https://doi.org/10.3390/cancers13143470